Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 2012-2016

  Nau, Roland ^a   Lassek, Christoph ^a   Kinzig Schippers, Martina ^b   Thiel, Andreas ^c   Prange, Hilmar W ^a   Sörgel, Fritz ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFOTAXIME; CLAVULANIC ACID; DEXAMETHASONE; GENTAMICIN; GLYCEROL; MANNITOL; MEROPENEM; METRONIDAZOLE;

ADULT; AGED; ANASTOMOSIS; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; FEMALE; HUMAN; HYDROCEPHALUS; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PLASMA HALF LIFE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031903271     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.2012     Document Type: Article

References (30)

1. Blaney, S. M., M. J. Daniel, A. J. Harker, K. Godwin, and F. M. Balis. 1995. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob. Agents Chemother. 39:2779-2782.
2. Buckley, M. M., R. N. Brogden, L. B. Barradell, and K. L. Goa. 1992. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 44:408-444.
3. Cabellos, C., J. Martinez-Lacasa, A. Martos, F. Tubau, A. Fernandez, P. F. Viladrich, and F. Gudiol. 1995. Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 39:2158-2160.
4. Chmelik, V., and J. Gutvirth. 1993. Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa. J. Antimicrob. Chemother. 32: 922-923.
5. Dagan, R., L. Velghe, J. L. Rodda, and K. P. Klugman. 1994. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J. Antimicrob. Chemother. 34:175-179.
6. Dealy, D. H., R. J. Duma, T. A. Tartaglione, L. A. Beightol, and P. M. Patterson. 1985. Penetration of primaxin (N-formimidoyl thienamycin and cilastatin) into human cerebrospinal fluid, abstr. S-78-4. In Abstracts of the 14th International Congress on Chemotherapy, Kyoto, Japan.
7. Donnelly, J. P., A. M. Horrevorts, R. W. Sauerwein, and B. E. de Pauw. 1992. High dose meropenem in meningitis due to Pseudomonas aeruginosa. Lancet 339:1117.
8. Edwards, J. R. 1995. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 36(Suppl. A):1-17.
9. Forward, K. R., H. D. Fewer, and H. G. Stiver. 1983. Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients. J. Neurosurg. 59: 389-394.
10. Gietz, J., H. Prange, and R. Nau. 1997. Pneumokokken-Sepsis und -Meningitis bei Erwachsenen nach Splenektomie, p. 17-29. In H. Prange and A. Bitsch (ed.), Bakterielle ZNS-Erkrankungen bei systemischen Infektionen. Steinkopff, Darmstadt, Germany.
11. Hutchinson, M., K. L. Faulkner, P. J. Turner, S. J. Haworth, W. Sheikh, H. Nadler, and D. H. Pitkin. 1995. A compilation of meropenem tissue distribution data. J. Antimicrob. Chemother. 36(Suppl. A):43-56.
12. Klugman, K. P., R. Dagan, and the Meropenem Meningitis Study Group. 1995. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob. Agents Chemother. 39:1140-1146.
13. Moore, C. M., and M. Ross. 1973. Acute bacterial meningitis with absent or minimal cerebrospinal fluid abnormalities. Clin. Pediatr. 12:117-118.
14. Murray, P. R., and A. C. Niles. 1990. In-vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates. Diagn. Microbiol. Infect. Dis. 13:57-61.
15. Nairn, K., G. L. Shepherd, and J. R. Edwards. 1995. Efficacy of meropenem in experimental meningitis. J. Antimicrob. Chcmother. 36(Suppl. A):73-84.
16. Nau, R., M. Kinzig-Schippers, F. Sörgel, S. Schinschke, R. Rössing, C. Müller, H. Kolenda, and H. W. Prange. 1997. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Antimicrob. Agents Chemother. 41:987-991.
17. Nau, R., and H. W. Prange. 1996. Estimation of steady state antibiotic concentration in cerebrospinal fluid from single-dose kinetics. Eur. J. Clin. Pharmacol. 49:407-109.
18. Nau, R., H. W. Prange, M. Kinzig, A. Frank, A. Dressel, P. Scholz, H. Kolenda, and F. Sörgel. 1996. Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies. Antimicrob. Agents Chemother. 40: 763-766.
19. Nau, R., H. W. Prange, P. Muth, G. Mahr, S. Menck, H. Kolenda, and F. Sörgel. 1993. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob. Agents Chemother. 37: 1518-1524.
20. Nau, R., T. Schmidt, K. Kaye, J. L. Froula, and M. G. Täuber. 1995. Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits. Antimicrob. Agents Chemother. 39:593-597.
21. Nau, R., F. Sörgel, and H. W. Prange. 1994. Lipophilicity at pH 7.4 and molecular size govern the entry of not actively transported drugs into the cerebrospinal fluid in humans with uninflamed meninges. J. Neurol. Sci. 122: 61-65.
22. Noetzel, M. J., and R. P. Baker. 1984. Shunt fluid examination: risks and benefits in the evaluation of shunt malformation and infection. J. Neurosurg. 61:328-332.
23. Norrby, S. R., P. A. Newell, K. L. Faulkner, and W. Lesky. 1995. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J. Antimicrob. Chemother. 36(Suppl. A):207-223.
24. Paris, M. M., S. M. Hickey, M. I. Uscher, S. Shelton, K. D. Olsen, and G. H. McCracken. 1994. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 38:1320-1324.
25. Pikis, A., J. A. Donkersloot, S. Akram, J. M. Keith, J. M. Campos, and W. J. Rodriguez. 1997. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 40:105-108.
26. Sawchuk, R. J., and M. A. Hedaya. 1990. Modeling the enhanced uptake of zidovudine (AZT) into cerebrospinal fluid. 1. Effect of probenecid. Pharm. Res. 7:332-338.
27. Schmutzhard, E., K. J. Williams, G. Vukmirovits, V. Chmelik, B. Pfausler, A. Featherstone, and the Meropenem Meningitis Study Group. 1995. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. J. Antimicrob. Chemother. 36 (Suppl. A):85-97.
28. Täuber, M. G., C. A. Doroshow, C. J. Hackbarth, M. G. Rusnak, T. A. Drake, and M. A. Sande. 1984. Antibacterial activity of β-lactam antibiotics in experimental meningitis due to Streptococcus pneumoniae. J. Infect. Dis. 149:568-574.
29. Wiseman, L. R., A. J. Wagstaff, R. N. Brogden, and H. M. Bryson. 1995. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73-101.
30. Zeneca GmbH. 1997. Data on file.